GlobeNewsWire
25 Aug 2026, 21:37 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The Phase 3 trial of Fianlimab failed to reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS). — Failure of a Phase 3 clinical trial is a major negative catalyst for biotech companies, directly impacting future revenue potential and drug approval prospects.
-0.80A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging securities fraud or other unlawful business practices. — While common in biotech after stock drops, securities litigation creates legal overhang and potential financial liabilities for the company.
-0.30Regeneron previously altered its Phase III Fianlimab-Libtayo Study to expand the number of patients eligible for progression-free survival analysis. — Changing study parameters mid-trial often signals to investors that initial results were underwhelming, increasing perceived risk of failure.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
